The rising burden of cognitive impairment across South Asia presents substantial clinical challenges for physicians. Accurate dementia subtype diagnosis remains vital to guide pharmacological treatment, optimize prognostic counseling, and address modifiable comorbidities. In low- and middle-income healthcare systems, clinicians often lack access to expensive molecular biomarkers such as amyloid positron emission tomography or cerebrospinal fluid assays. Consequently, structured clinical assessment combined with accessible magnetic resonance imaging visual rating scales provides a critical diagnostic backbone. The Community Awareness and Research on Early Dementia (CARED) study delivers timely, real-world evidence from a large clinical cohort in Bangladesh. These findings shed significant light on age differentials, vascular risk profiles, and neuroimaging utility across diverse presentations of cognitive decline.

Epidemiologic Patterns and Age Disparities Across Subtypes

In this cross-sectional investigation, researchers evaluated 658 consecutive adults presenting with cognitive impairment at a tertiary neurological center. A multidisciplinary clinical panel established formal diagnoses using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria. Alzheimer's-related dementia represented the majority of presentations, accounting for 51.7% of all confirmed cases. However, the analysis identified striking variations in chronological age at presentation across distinct diagnostic categories. Patients with Alzheimer's-related dementia received their diagnosis at a significantly older average age of 67.7 years. In contrast, individuals presenting with non-Alzheimer's-related dementias received diagnoses at a younger mean age of 64.3 years.

Furthermore, stepwise multivariable linear regression confirmed that non-Alzheimer's pathology predicted a formal diagnosis 4.3 years earlier than Alzheimer's disease. Patients diagnosed with pseudodementia presented at an even earlier age, highlighting the critical need to distinguish affective illness from progressive neurodegeneration. These observations align closely with broader epidemiological trends observed across the Indian subcontinent. Early cognitive complaints frequently stem from diverse metabolic, psychiatric, or frontotemporal etiologies. Therefore, physicians must maintain vigilance when evaluating middle-aged individuals presenting with subtle executive dysfunction or behavioral changes.

Vascular Risk Factors and Dementia Subtype Diagnosis

Vascular pathology plays a prominent and aggressive role in cognitive deterioration throughout South Asia. Within the CARED cohort, multivariable logistic regression demonstrated powerful associations between modifiable cardiovascular risk factors and cerebrovascular cognitive decline. Specifically, chronic systemic hypertension increased the odds of vascular dementia by more than fourfold. Even more dramatically, active cigarette smoking elevated the odds of developing vascular dementia by over thirteenfold. Consequently, vascular brain injury emerges as a primary, preventable contributor to regional neurocognitive impairment.

Moreover, these robust risk associations highlight an actionable clinical window for primary care physicians and specialists alike. Hypertension causes persistent cerebral small vessel arteriolosclerosis, which impairs subcortical white matter tracts and disrupts critical frontal networks. Similarly, tobacco exposure accelerates systemic endothelial dysfunction and neuroinflammation. Because mixed dementia frequently coexists alongside classic Alzheimer's pathology in older adults, addressing vascular drivers provides substantial clinical dividends. Therefore, clinicians must aggressively treat midlife hypertension, facilitate smoking cessation, and optimize glycemic control. Integrating rigorous vascular risk factor management into routine memory clinic pathways directly attenuates secondary brain injury and delays disease progression.

Medial Temporal Atrophy in Subtype Discrimination

Structural magnetic resonance imaging serves as an indispensable modality in the standard workup of cognitive deterioration. The CARED investigators systematically assessed the discriminatory performance of standardized visual rating scales across confirmed dementia subtypes. To evaluate medial temporal lobe degeneration, clinicians applied the validated Scheltens Medial Temporal Atrophy (MTA) scale. Receiver operating characteristic analyses confirmed that MTA demonstrated strong discriminatory accuracy for Alzheimer's-related dementia, achieving an area under the curve of 0.752.

Importantly, hippocampal and entorhinal atrophy represents the hallmark macroscopic feature of early amnestic Alzheimer's pathology. Visual MTA scoring offers a rapid, highly reproducible method that general radiologists and neurologists can implement without costly automated volumetric software. However, clinicians must interpret MTA scores within an age-appropriate framework because physiological aging also causes subtle volume loss. Furthermore, significant medial temporal volume loss may occasionally occur in advanced vascular insults or frontotemporal lobar degeneration. Consequently, while a high MTA score strongly supports an Alzheimer's diagnosis, physicians must synthesize imaging findings with bedside neuropsychological testing. This balanced approach prevents misclassification and sharpens clinical decision-making in busy resource-limited practice environments.

Evaluating White Matter Hyperintensities with the Fazekas Scale

Cerebral small vessel disease represents an pervasive finding on neuroimaging in South Asian elders. In the CARED study, researchers utilized the Fazekas visual rating scale to quantify both periventricular and deep white matter hyperintensities. The Fazekas scale demonstrated exceptional discriminatory capacity for vascular dementia, yielding an outstanding area under the curve of 0.838. Similarly, the scale achieved an area under the curve of 0.836 in identifying mixed dementia cases.

These compelling statistical metrics affirm that severe confluent white matter lesions strongly reflect clinically meaningful vascular cognitive impairment. Nevertheless, clinicians must recognize that punctate or mild white matter changes frequently occur alongside normal aging. Furthermore, white matter hyperintensities commonly accompany pure amyloid pathology due to concurrent cerebral amyloid angiopathy. Therefore, clinicians should not view an isolated elevated Fazekas score as definitive evidence of exclusive vascular dementia. Instead, physicians should consider extensive white matter lesions as clear proof of cerebrovascular burden that exacerbates underlying neurodegeneration. When interpreted alongside focal neurological signs and step-wise functional decline, Fazekas grading provides indispensable objective support for tailoring patient management.

Global Cortical Atrophy and Posterior Changes

The study also evaluated broader structural patterns using the Global Cortical Atrophy (GCA) scale and the Koedam posterior atrophy scale. The GCA scale demonstrated moderate discriminatory performance in differentiating frontotemporal dementia, producing an area under the curve of 0.659. Frontotemporal dementia typically presents with pronounced frontal and anterior temporal sulcal widening, which drives early behavioral changes, disinhibition, and prominent language deficits.

In contrast, the Koedam visual rating scale demonstrated relatively poor discriminatory performance within this clinical cohort. This limited utility likely reflects the low prevalence of atypical posterior cortical presentations and the subjective difficulty of grading parietal atrophy on routine scans. Consequently, routine visual scoring provides the greatest clinical value when assessing anterior cortical changes and medial temporal structures. Additionally, multivariable modeling demonstrated that GCA and Fazekas scores independently correlated with age at presentation. Older individuals naturally accumulated higher cumulative atrophy and microvascular damage. Clinicians must therefore avoid over-interpreting generalized volume loss in elderly patients without corroborating functional deficits. Structured reporting systems substantially enhance diagnostic precision when clinicians combine these visual scales systematically.

Translational Relevance for Clinical Practice in India

The clinical findings from the CARED study offer direct translational relevance for medical practitioners across India. Both nations share comparable demographic transitions, marked by rapidly aging populations, surging cardiovascular disease, and high rates of unrecognized dementia. Moreover, Indian healthcare centers face similar economic and infrastructural barriers regarding specialized biomarker infrastructure. By establishing that non-Alzheimer's presentations emerge years earlier, this research reminds physicians to evaluate younger adults thoroughly for atypical or reversible causes of decline.

Furthermore, the prominent contribution of hypertension and smoking reinforces that aggressive cardiovascular primary prevention directly protects cognitive health. Indian clinical guidelines should advocate for the routine adoption of structured visual rating scales in radiology reporting templates. Implementing the MTA, Fazekas, and GCA scales into everyday neuroimaging evaluations requires no additional financial expenditure or expensive equipment. Instead, standardized visual scoring bridges the gap between primary care referrals and tertiary neurology management. Ultimately, combining rigorous cardiovascular control, disciplined neuroimaging grading, and multidisciplinary clinical evaluation provides an accessible, evidence-based paradigm for optimizing dementia care across South Asia.

How does the CARED study differentiate Alzheimer's from non-Alzheimer's dementias?

The study found that Alzheimer's-related dementia presented at an older average age of 67.7 years, whereas non-Alzheimer's subtypes appeared 4.3 years earlier. Additionally, structured neuroimaging provided key distinctions. The medial temporal atrophy scale demonstrated good accuracy for Alzheimer's pathology, whereas Fazekas scores strongly discriminated vascular and mixed dementias.

Why are visual MRI rating scales valuable in resource-limited settings?

Visual MRI scales, such as MTA and Fazekas grading, require no costly automated software or expensive PET tracers. Consequently, clinicians can immediately quantify regional brain atrophy and vascular white matter lesions. These accessible tools enhance diagnostic accuracy and standardize radiological reporting during routine multidisciplinary evaluations for suspected neurocognitive impairment.

What modifiable risk factors showed the strongest link to vascular dementia?

Hypertension and active cigarette smoking demonstrated the strongest statistical associations with vascular dementia in the CARED cohort. Hypertension increased the odds of vascular dementia by over fourfold, while smoking increased the odds thirteenfold. Therefore, aggressive midlife blood pressure management and tobacco cessation represent vital clinical interventions to prevent cognitive impairment.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Ranjan R et al. Age at dementia diagnosis, subtype associations, and neuroimaging differentiation in Bangladesh: The CARED study. PLoS One. 2026. doi: 10.1371/journal.pone.0359109. PMID: 42789572.
2. Harper L, Barkhof F, Scheltens P, Fox NC, Schott JM. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry. 2014;85(6):692-698.
3. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.